HCC fast facts:

6th most common cancer

6th most commonly diagnosed cancer accounting for 4.7% of all new cancer cases1

Hepatocellular carcinoma represents 90% of primary liver cancers2

3rd largest cause of cancer deaths

3rd largest cause of cancer deaths worldwide1

Number 3 leading cause of cancer deaths globally, accounting for 8% of all cancer mortality in 20201

survival rate

5-year survival rate between 10-20%

830K deaths in 2020, with 1.1M projected in 20301

The global incidence of liver cancer is increasing, growing 3% per year in Asia and Europe, and around 1-2% in the United States

Identifying HCC patients at very early stage (stage 0) is a huge clinical unmet need

Current imaging diagnostics offer poor sensitivity for small lesions (1-2cm)

Median’s iBiopsy® HCC

Unrivalled AI/ML Software as Medical Device (SaMD) enabling very early HCC diagnosis with unprecedented performance

  • The only end-to-end AI/ML tech-based CADe/CADx SaMD for very early stage HCC

  • Indicated for the detection, localization, and characterization of small nodules below 2cm

  • Unprecedented sensitivity and specificity versus standard of care

  • A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA

    Additional indications

    Lung cancer

    Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)

    Liver fibrosis

    Liver fibrosis in non-alcoholic steatohepatitis (NASH)

    Latest news


    Median Technologies to participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with two presentations on iBiopsy®


    Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device


    Median Technologies announces design completion of its iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance


    Median Technologies files FDA 513(g) regulatory submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device